Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425641 | 0.84 | GAA (0.53) | L3MBTL1TDP1GAAKDM4ERAB9A | |
| SCHEMBL30031533 | 0.84 | GAA (0.53) | L3MBTL1TDP1GAAKDM4ERAB9A | |
| SCHEMBL2438709 | 0.83 | ATR (0.38) | ATRP2RX3KDM4ELMNAGABRA1 | |
| SCHEMBL24342423 | 0.83 | ATR (0.38) | ATRP2RX3KDM4ELMNAGABRA1 | |
| SCHEMBL18298896 | 0.83 | ATR (0.43) | ATRP2RX3LMNAGABRA1GABRG2 | |
| SCHEMBL30726361 | 0.83 | ATR (0.43) | ATRP2RX3LMNAGABRA1GABRG2 | |
| SCHEMBL21702390 | 0.82 | POLB (0.41) | L3MBTL1TDP1GAAKDM4ERAB9A | |
| SCHEMBL30046812 | 0.82 | POLB (0.41) | L3MBTL1TDP1GAAKDM4ERAB9A | |
| SCHEMBL2435446 | 0.82 | ATR (0.49) | ATRGAAP2RX3KDM4ELMNA | |
| SCHEMBL4001036 | 0.81 | ATR (0.39) | ATRGAAP2RX3LMNAKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111295382-A | Bridged bicyclic compounds as modulators of farnesoid X receptors | 百时美施贵宝公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20170240511-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240511-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240511-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3204384-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054806-A1 | SUBSTITTUED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057743-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054806-A1 | SUBSTITTUED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057743-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | L3MBTL1 4007/4885TDP1 4565/4885ATR 3968/4885 |
| US-20170240511-A1 | SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, EGLN2, EGLN3 | L3MBTL1 4383/4885TDP1 4664/4885ATR 4297/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | L3MBTL1 4007/4885TDP1 4565/4885ATR 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.